Latest Breaking News On - Prnewswire compugen ltd - Page 1 : comparemela.com

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesTel avivYvonne naughtonZoya alteberAssaf menachemCompugen ltdStock exchangeCorporate communicationsPrnewswire compugen ltdKeystone symposiumBeyond immune checkpoint blockadeOvercoming resistanceAntibody induces potent immuneAnti tumor effectsUniquely expressed

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

HOLON, Israel, Feb. 20. 2024 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will.

Tel avivSan franciscoUnited statesYvonne naughtonStock exchangePrnewswire compugen ltdCorporate communicationsCompugen ltdInvestor relations

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled.

San franciscoUnited statesTel avivIsrael generalYvonne naughtonPrnewswire compugen ltdCorporate communicationsStock exchangeSecurities exchangeExchange commissionAnat cohen dayagChief executive officerSecurities actSecurities exchange actPrivate securities litigation reform actAnnual report

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024,.

San franciscoUnited statesTel avivYvonne naughtonNasdaq stock marketStock exchangeListing qualifications departmentCorporate communicationsPrnewswire compugen ltdCompugen ltdNasdaq listing ruleBid priceMinimum bid priceMinimum bid price requirementNotification letterInvestor relations

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a.

San franciscoUnited statesTel avivYvonne naughtonStock exchangeCorporate communicationsPrnewswire compugen ltdCompugen ltdInvestor relations